News Focus
News Focus
Followers 26
Posts 2016
Boards Moderated 0
Alias Born 01/11/2012

Re: SidVicious post# 27573

Monday, 02/19/2018 9:19:26 AM

Monday, February 19, 2018 9:19:26 AM

Post# of 32075

you are using a typo to deflect from the fact none of you can point to anything he's done that shows he can take a failing drug and make it successful.

That's absolutely a huge fail



New investor here, but have followed for quiet awhile. Let me see if I understand your presumption. You're intimating that Dr. Kendall has not done anything in his career that would be beneficial to Mannkind, therefore this hire is a waste of resources, or at best a non-event?

From my experience working for large multi-billion dollar corporations, senior executives are not typically not given positions of responsibility if they are not extremely bright, capable of developing & driving strategy, making effective change, and in the case of public companies, build shareholder value.

According to the press release, and documentation subsequently filed with the SEC, the general consensus about Dr. Kendall is very different than yours.

[quote]Dr. Kendall's career includes over 30 years of experience in diabetes and metabolism research, clinical management, research, and policy advocacy. Most recently, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and during that time was responsible for all medical affairs activities and guided research and development strategy across multiple geographies. In this role, he worked to re-establish Lilly Diabetes as a world class medical organization — and added to his extensive experience with both injected and mealtime insulins, as well as devices and continuous glucose monitors. Prior to joining Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals. He received his M.D. and completed his Post Graduate Medical Training at the University of Minnesota, and earned a B.A. in Biology from St. Olaf College



This information seems so much more reliable than an anonymous message board poster who continuously spams negative opinions about Mannkind. In my opinion, Dr. Kendall joining MNKD is a very positive sign that he sees real promise.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNKD News